Biovica – Biomarkers for measuring cell proliferation


Biovica is a biotech company focused on the development of biomarkers as companion diagnostics in the field of cancer. Biovica’s DiviTum™ assay has a documented ability to predict treatment outcome and has the potential to become a marker of therapeutic efficacy for new cancer drugs.

Many cancer patients do not respond to current therapies and, over time, tumors can become resistant to therapy. Thus, diagnostic tools are needed to select the right drug for the right patient at the right time. A validated biomarker assay, such as Biovica’s DiviTum™, can improve treatment decisions, resulting in a better outcome for the patient.

Biovica collaborates with institutes, such as the Karolinska Institute and the Dana-Farber Cancer Institute, as well as pharmaceutical companies, in evaluating DiviTum™, as well as in developing a new generation of cancer therapies targeting cell proliferation.

DiviTumRespondersCancer biomarkers can help assure that the right patient can receive the right therapy, which can prolong life and improve outcome.


Biovica’s DiviTum™: The Most Sensitive Serum Thymidine Kinase Assay with Several Companion Diagnostic Applications

DiviTum™ measures the activity of the enzyme thymidine kinase (TK) in serum. Thymidine kinase is an enzyme expressed during the G1/S phase of the cell cycle and is a fundamental enzyme in DNA synthesis. The expression of TK is E2F-dependent; therefore, there is a strong scientific rationale for an association between TK activity and the effectiveness of new drugs targeting cell cycle regulation mechanisms.

Biovica’s DiviTum™ is being evaluated as a tool in developing new cancer therapies at some of the world’s leading cancer institutes and pharmaceutical companies.